Drug name - Invokana

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(5 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

CN1829728A JANSSEN PHARMS Novel Compounds
Oct, 2011

(10 years ago)

CN101111492B JANSSEN PHARMS Indole Derivatives
Mar, 2017

(5 years ago)

CN101111492A JANSSEN PHARMS Indol Derivative
Mar, 2017

(5 years ago)

CN103214471B JANSSEN PHARMS Preparation Method Of Compound With Sodium-Dependent Glucose Transporter Inhibitory Activity
Jul, 2024

(1 year, 9 months from now)

CN103214471A JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

CN101573368B JANSSEN PHARMS Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

CN101573368A JANSSEN PHARMS A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum.
Dec, 2027

(5 years from now)

IN200600734P4 JANSSEN PHARMS Glucopyranoside Compound
Jul, 2024

(1 year, 9 months from now)

IN232231B JANSSEN PHARMS 1-(-D-Glucopyranosyl)-3-(2-Thienylmethyl)Benzene Derivatives
Jul, 2024

(1 year, 9 months from now)

IN200903871P4 JANSSEN PHARMS Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

IN286412B JANSSEN PHARMS Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2896397B2 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP1654269A1 JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

EP3251679A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2514756B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP3251679B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP1654269B1 JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

EP2896397B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2514756A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2896397A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2102224B1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224A1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224B2 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP1651658B2 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

EP1651658A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

EP1651658B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound Apr, 2025

(2 years from now)

US10617668 JANSSEN PHARMS Pharmaceutical formulations May, 2031

(8 years from now)

Drugs and Companies using CANAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; treatment of type 2 diabetes mellitus with 300 mg canagliflozin per day; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus with 100 mg canagliflozin per day; treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.